{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:24:30Z","timestamp":1790634270429,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtha.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T21:57:52Z","timestamp":1679090272000},"page":"1503-1514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII"],"prefix":"10.1016","volume":"21","author":[{"given":"Behnaz","family":"Pezeshkpoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Sereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Cristin","family":"Berkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Matuschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.03.011_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1055\/s-0034-1395161","article-title":"Historical review on genetic analysis in hemophilia A","volume":"40","author":"Oldenburg","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00001721-199108000-00007","article-title":"Genetics and molecular biology of haemophilias A and B","volume":"2","author":"Green","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.03.011_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2023.03.011_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.03.011_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201374 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.03.011_bib6","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"Tiede","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cellimm.2015.12.006","article-title":"ABIRISK consortium. Immunogenicity of long-lasting recombinant factor VIII products","volume":"301","author":"Ing","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2023.03.011_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/hae.12428","article-title":"Novel products for haemostasis - current status","volume":"20","author":"Oldenburg","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib9","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1055\/a-1282-2251","article-title":"Extended half-life factor VIII\/factor IX products: assay discrepancies and implications for hemophilia management","volume":"40","author":"M\u00fcller","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2023.03.011_bib10","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2013-07-498261","article-title":"Molecular approaches for improved clotting factors for hemophilia","volume":"122","author":"Kaufman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib11","article-title":"Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications","volume":"2012","author":"Banerjee","year":"2012","journal-title":"J\u00a0Drug Deliv"},{"key":"10.1016\/j.jtha.2023.03.011_bib12","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-019-01152-7","article-title":"Damoctocog alfa pegol: a review in haemophilia A","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2023.03.011_bib14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","article-title":"A\u00a0novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models","volume":"121","author":"Stennicke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib15","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide","volume":"118","author":"\u00d8stergaard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.03.011_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jth.14959","article-title":"Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2","volume":"18","author":"Giangrande","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/jth.15665","article-title":"Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines","volume":"20","author":"Hirsiger","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.jtha.2023.03.011_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2516.2008.01924.x","article-title":"Diagnosis and quantification of factor VIII inhibitors","volume":"16","author":"Verbruggen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib21","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.jtha.2023.03.011_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)\u2013protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtha.2023.03.011_bib23","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.03.011_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2008-02-124941","article-title":"Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A","volume":"112","author":"Lacroix-Desmazes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-0038-1657777","article-title":"ABIRISK consortium. Inhibitor formation in congenital hemophilia A: an immunological perspective","volume":"44","author":"Delignat","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein PEGylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtha.2023.03.011_bib27","first-page":"315","article-title":"Immunotherapy with monomethoxypolyethylene glycol modified allergens","volume":"6","author":"Dreborg","year":"1990","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.jtha.2023.03.011_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0005-2795(79)90111-9","article-title":"Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol","volume":"578","author":"Savoca","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jtha.2023.03.011_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0192-0561(85)90158-4","article-title":"Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase","volume":"7","author":"Tsuji","year":"1985","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.jtha.2023.03.011_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.2042-7158.1995.tb05835.x","article-title":"Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration","volume":"47","author":"Yamaoka","year":"1995","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jtha.2023.03.011_bib31","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2010-11-316521","article-title":"Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model","volume":"118","author":"van Helden","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1084\/jem.61.5.643","article-title":"Studies on the sensitization of animals with simple chemical compounds","volume":"61","author":"Landsteiner","year":"1935","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtha.2023.03.011_bib33","first-page":"1493","article-title":"A\u00a0systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A","volume":"23","author":"Graf","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jtha.2023.03.011_bib34","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1111\/jth.12912","article-title":"Longer-acting clotting factor concentrates for hemophilia","volume":"13","author":"Powell","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib36","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/hae.13875","article-title":"PEGylated biologics in haemophilia treatment: current understanding of their long-term safety","volume":"26","author":"Baumann","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib38","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13963","article-title":"PROTECT VIII kids: BAY 94\u20139027 (PEGylated recombinant factor VIII) safety and efficacy in previously treated children with severe haemophilia A","volume":"26","author":"Santagostino","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib39","article-title":"Efficient polyethylene glycol (PEG) mediated transformation of the moss Physcomitrella patens","volume":"50","author":"Liu","year":"2011","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.jtha.2023.03.011_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jtha.2023.03.011_bib41","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jtha.2023.03.011_bib42","series-title":"PEGylated protein drugs: basic science and clinical applications","first-page":"147","article-title":"The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)","author":"Armstrong","year":"2009"},{"key":"10.1016\/j.jtha.2023.03.011_bib43","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","article-title":"The mystery of antibodies against polyethylene glycol (PEG) - what do we know?","volume":"33","author":"Lubich","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.jtha.2023.03.011_bib44","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.jtha.2023.03.011_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2023.03.011_bib46","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1111\/hae.14297","article-title":"Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94\u20139027 in severe haemophilia A: final results of the PROTECT VIII extension study","volume":"27","author":"Reding","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/hae.14294","article-title":"PROTECT VIII kids extension study: long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.011_bib48","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib49","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.03.011_bib50","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/bloodadvances.2021005745","article-title":"Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors","volume":"6","author":"Schweiger","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.03.011_bib51","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib52","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.V83.5.1278.1278","article-title":"Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes","volume":"83","author":"Wolf","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.011_bib53","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2249.1996.d01-793.x","article-title":"Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes","volume":"105","author":"Wolf","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtha.2023.03.011_bib54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2249.2005.02779.x","article-title":"Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells","volume":"140","author":"Olas","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtha.2023.03.011_bib55","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"INSIGHT Study Group. Inhibitor development and mortality in non-severe hemophilia A","volume":"13","author":"Eckhardt","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/bloodadvances.2022008989","article-title":"Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination","volume":"7","author":"Valsecchi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.03.011_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180456","article-title":"An in silico and in\u00a0vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII","volume":"12","author":"Pezeshkpoor","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtha.2023.03.011_bib58","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH13-08-0690","article-title":"Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays","volume":"111","author":"Pavlova","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.011_bib59","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-019-03691-1","article-title":"In silico and in\u00a0vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies","volume":"98","author":"Pezeshkpoor","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2023.03.011_bib60","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:15Z","timestamp":1761536295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623002416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1538783623002416"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}